Bernhard Ehmer, the former chief executive of Imclone Systems Corp (Eli Lilly and Company), is chief executive-designate at Biotest AG, the German biologics company. He is scheduled to take over the CEO position from Gregor Schulz on 1 January 2015. Dr Ehmer obtained a PhD in medicine and was a resident in internal medicine at the University of Heidelberg’s teaching hospital. He started his career in the pharmaceutical industry at Boehringer Mannheim and subsequently worked at Merck KGaA. He was also CEO of Fresenius Biotech GmbH before heading up Imclone.
Biotest announced the appointment on 9 July 2014.
Copyright 2014 Evernow Publishing Ltd